Goi G, Lombardo A, Fabi A, Burlina A B, Segalini G, Guagnellini E, Tettamanti G
Dipartimento di Chimica e Biochimica Medica, Università di Milano, Italy.
Acta Diabetol Lat. 1987 Oct-Dec;24(4):331-40. doi: 10.1007/BF02742966.
Several lysosomal enzymes (beta-N-acetyl-D-glucosaminidase, beta-D-glucuronidase, alpha-D-galactosidase, beta-D-galactosidase, alpha-D-glucosidase, beta-D-glucosidase, alpha-L-fucosidase and alpha-D-mannosidase) were determined in the serum of 54 non-insulin-dependent diabetics with different degrees of metabolic control and without complications and in 18 non-insulin-dependent diabetics with complications. The serum levels of beta-N-acetyl-D-glucosaminidase, beta-D-glucuronidase, alpha-D-galactosidase, and alpha-D-mannosidase were significantly (p less than 0.01) higher in the diabetics without complications. The levels of beta-N-acetyl-D-glucosaminidase and beta-D-glucuronidase were inversely proportional to the degree of metabolic control, in a statistically significant manner. Moreover the levels of these enzymes decreased to normal values during a 2-month period of controlled oral hypoglycemic drug-diet therapy resulting in metabolic compensation. The presence of complications was indicated by a further increase of serum beta-N-acetyl-D-glucosaminidase and beta-D-glucuronidase; however the portion of lysosomal enzyme activities due to complications remained unchanged after controlled therapy aimed at compensating the metabolism. The conclusion is drawn that in non-insulin-dependent diabetics, as already shown for insulin dependent-diabetics, serum lysosomal enzymes, especially beta-N-acetyl-D-glucosaminidase and beta-D-glucuronidase, are good intraindividual indicators of the metabolic control of the disease.
在54例代谢控制程度不同且无并发症的非胰岛素依赖型糖尿病患者以及18例有并发症的非胰岛素依赖型糖尿病患者的血清中,测定了几种溶酶体酶(β-N-乙酰-D-氨基葡萄糖苷酶、β-D-葡萄糖醛酸酶、α-D-半乳糖苷酶、β-D-半乳糖苷酶、α-D-葡萄糖苷酶、β-D-葡萄糖苷酶、α-L-岩藻糖苷酶和α-D-甘露糖苷酶)。无并发症的糖尿病患者血清中β-N-乙酰-D-氨基葡萄糖苷酶、β-D-葡萄糖醛酸酶、α-D-半乳糖苷酶和α-D-甘露糖苷酶的水平显著更高(p<0.01)。β-N-乙酰-D-氨基葡萄糖苷酶和β-D-葡萄糖醛酸酶的水平与代谢控制程度呈负相关,具有统计学意义。此外,在为期2个月的口服降糖药-饮食控制治疗导致代谢得到补偿的期间,这些酶的水平降至正常。并发症的存在表现为血清β-N-乙酰-D-氨基葡萄糖苷酶和β-D-葡萄糖醛酸酶进一步升高;然而,在旨在补偿代谢的控制治疗后,由并发症导致的溶酶体酶活性部分保持不变。得出的结论是,在非胰岛素依赖型糖尿病患者中,如同已在胰岛素依赖型糖尿病患者中所显示的那样,血清溶酶体酶,尤其是β-N-乙酰-D-氨基葡萄糖苷酶和β-D-葡萄糖醛酸酶,是疾病代谢控制的良好个体内指标。